Common toxicities of mammalian target of rapamycin inhibitors

Research output: Contribution to journalReview articlepeer-review

91 Scopus citations


The toxicities of newer targeted therapies are different from those seen with the traditional chemotherapy. Mammalian target of rapamycin (mTOR) inhibitors are evolving into an important class of drugs in oncology, and this class of drugs presents with a variety of different toxicities. Although similar to the toxicities seen in transplantation, these rapamycin analogs have unique side effects when compared to traditional chemotherapy agents. While most of the toxicities are mild, few can be severe and require routine monitoring. Mucositis and rash are the most common side effects. The metabolic toxicities, hyperglycemia, hyperlipidemia, and hypophosphatemia are different from the side effects traditionally seen with chemotherapy. This review will focus on the common toxicities seen with the mTOR inhibitors.

Original languageEnglish (US)
Pages (from-to)125-129
Number of pages5
JournalTargeted Oncology
Issue number2
StatePublished - Jun 2011


  • Everolimus
  • Radaforolimus
  • Temsirolmus
  • Toxicity
  • mTOR inhibitors

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Oncology
  • Cancer Research


Dive into the research topics of 'Common toxicities of mammalian target of rapamycin inhibitors'. Together they form a unique fingerprint.

Cite this